HighLife SAS, a Paris, France-based medtech company focused on the development of a transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, closed a €32m Series B equity financing round.
The round was co-led by U.S. Venture Partners and Andera Partners, with participation from Sofinnova Partners, Sectoral Asset Management, and Jose Calle Gordo, Chairman of HighLife.
The company intends to use the funds to complete the development of its transcatheter transseptal mitral valve implantation program, which includes regulatory approval trials in Europe to obtain the CE mark and a first clinical trial in the U.S. via an Early Feasibility Study (EFS).
Founded in 2010 by Georg Börtlein, Founder, HighLife focuses on the development of a novel transcatheter replacement system for treating mitral regurgitation. The company’s technology targets optimal treatment outcomes as it can be delivered transseptally via the femoral vein in a reversible manner, and self-locates inside the native annulus.
HighLife also has offices in Irvine (California).